Management Of Lassa Fever in a Resource Limited Setting: Experience From Irrua Specialist Teaching Hospital Main author: Gloria Esoimeme Co-authors:

Slides:



Advertisements
Similar presentations
* Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. * EBOLA is a rare but deadly virus.
Advertisements

Any of the following risk factors within 3 weeks (21 days) before onset of symptoms 1,2 : Contact with blood or other body fluids of a patient known to.
Bioterrorist Agents: Tularemia
EVD is a preventable but often fatal viral infection An EVD outbreak is affecting countries in West Africa where disease control resources are very limited.
Determination of Case Classification for Reportable Medical Events John Ambrose, MPH, CHES Epidemiologist / Army DRSi Project Manager U.S. Army Public.
Ebola Virus Disease. EVD Description Hemorrhagic fever with case fatality rate up to 90% Endemic areas: Central and West Africa Wildlife reservoir: bats.
Ebola Virus. What is Ebola hemorrhagic fever? Ebola hemorrhagic fever (Ebola HF) is a severe, often-fatal disease in humans and nonhuman primates (monkeys,
 Ebola is a virus, or a microscopic organism consisting of genetic material in Africa that has caused many deaths, and is named after the Ebola River.
EBOLA OUTBREAK 2014 There has never been an outbreak this size and severity.
Inaugural Conference of the African Health Economics and Policy Association (AfHEA) Accra - Ghana, 10th - 12th March 2009 Patent medicines vendors a resource.
Q Fever By: Mandana Ershadi-Hurt. Q fever is a zoonotic disease caused by Coxiella burnetii, a species of bacteria that is distributed globally. Q fever.
Welcome to Journal club Dr. Md. Abul Hossain Khan Honorary Trainee Department of microbiology, MMC A Comparative Study of Typhidot and Widal Test in Patients.
Judith Pinkham (Ph.D. Student) Walden University PUBH 8165 Instructor: Dr. Fredric Grant Summer 2013.
INTEGRIS Preparedness Plan: Ebola Virus Disease (EVD) With the spread of Ebola to the U.S., ensuring our employees and communities are safe is the utmost.
Copyright © 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2002 by Saunders, an imprint of Elsevier Inc. Slide 1 CHAPTER 31 INPATIENT CODING.
EBOLA Virus Disease August 22, What is Ebola Virus Disease (EVD)? Ebola virus disease (also known as Ebola hemorrhagic fever) is a severe, often-fatal.
About Swine Flu Dr.Kedar Karki. What is Swine Influenza? Swine Influenza (swine flu) is a respiratory disease of pigs caused by type A influenza virus.
Babesiosis 1 st Quarter 2011 DIDE Training Jonah Long, MPH 1.
Laboratory Investigation
Ebola virus  The Ebola virus causes an acute, serious illness which is often fatal if untreated.  The most severely affected countries are: Guinea,
Rationale Ebola is a virus that greatly effects not only the human population in various parts of the world, but also in animals such as chimpanzees and.
Severe Acute Respiratory Syndrome (SARS) Michael Leonard.
 An acute, severe viral infection  First appeared in 1976 in two simultaneous outbreaks  in a village near the Ebola River in the Democratic Republic.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
DR. MOHAMMED ARIF. ASSOCIATE PROFESSOR AND CONSULTANT VIROLOGIST. Non-arboviruses associated with zoonotic diseases.
Outbreaks and Epidemics Ebola Hemorrhagic Fever. Ebola facts and origins  Ebola hemorrhagic fever is a severe, often-fatal disease in humans and nonhuman.
Tropical Fevers Case 1: 27 year old woman comes to a local health unit with history of a gradual onset of fever and headache and loss of appetite over.
Integrated Management of Childhood Illnesses
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.
Information on the Ebola surge in West Africa All you need to know about Ebola (HF) -Jazlyn Selvasingh.
Diagnostic Testing for Zika Virus Frederick S. Nolte, PhD, D(ABMM), F(AAM) Professor and Vice-Chair for Laboratory Medicine Department of Pathology and.
MUMPS MUMPS.
DR I.O.LAWAL MBChB(Ife),FWACS(Urol). EBOLA VIRUS DISEASE Introduction Epidemiology Transmission Signs & Symptoms Diagnosis Differentials Treatment/ Health.
VIRAL HAEMORRHAGIC FEVERS BY DR UCHE UNIGWE. Lassa fever Yellow fever Marburg/Ebola HF Dengue HF Crimean- Congo HF Hanta virus HF.
Crimean-Congo Fever- A Serious Threat For Public Health
Outbreak Investigation
Erwan Piriou, PhD Laboratory advisor, Médecins Sans Frontières
Ebola Facts October 14, 2014.
Fig. 1 Respondents bitten by dogs in the last 12 Months
VIRAL INFLUENZA.
Presentation on Mumps
Infection Control Q and A APIC Greater NY Chapter 13 May 17, 2017 Beth Nivin BA MPH NYC DOHMH Communicable Disease Program
Ebola Virus and development
Dr. JAMAL R Al-Rawi, MBChB, MSc, FICMS
VIRAL HAEMORRHAGIC FEVERS
From: Clinical and Laboratory Diagnosis of Dengue Virus Infection
Medical English Group 5 Meningitis.
Yellow fever deepak b. saxena.
BY DR. MUDAMA PRECIOUS (M.B.B.S., BENIN)
Ebola Facts October 14, 2014.
H1N1 Swine Flu Overview by ziffi.com Symptoms, Causes, Prevention, Tests, Test & Vaccination Centers.
Epidemiological Updates on Outbreaks and Public Health Emergencies in AFRO Region 20 April 2018 WHO Health Emergencies, WHO Liberia Country Office.
Ebola Virus Disease (EVD) WHAT IS IT?
Controlling the risk of Chikungunya
Six stage journey When diagnosed with a brain tumour.
Dengue Virus Infections Investigation Guideline
Ebola Facts October 14, 2014.
EBOLA VIRUS DISEASE Joseph P. Iser, MD, DrPH, MSc Southern Nevada Health District.
EDO UNIVERSITY IYAMHO FACULTY OF SCIENCE SEMINAR SERIES
Diagnosed Food Handlers
Content Public Health Emergencies Lassa Fever: Nigeria
Introduction To Medical Technology
Coronaviruses Co Vs..
Ebola Facts October 14, 2014.
Figure 1. Flow diagram of infant measles mortality case-control study population and sample. The study population was ... Figure 1. Flow diagram of infant.
Ebola Facts October 14, 2014.
Detection of Ebola virus infection in nonfatal versus fatal cases.
Philip Huang, MD, MPH Director/ Health Authority
Presentation transcript:

Management Of Lassa Fever in a Resource Limited Setting: Experience From Irrua Specialist Teaching Hospital Main author: Gloria Esoimeme Co-authors: Vivian Ogbonna, Juliet Idialu-Eigbobo, Danny Asogun

Introduction Lassa fever is a zoonotic viral hemorrhagic fever endemic in West Africa It is challenging to make a diagnosis of Lassa fever using only clinical features because of the similarity in symptoms between Lassa Fever and other common tropical illnesses  The diagnosis of Lassa fever is done routinely with indirect fluorescent-antibody test, enzyme-linked immunosorbent assays for Lassa virus antigen and immunoglobulin G and M antibodies The gold standard is the reverse transcription-polymerase chain reaction (RT-PCR) Most Lassa fever endemic areas are resource limited and the hospital laboratories are not equipped to carry out the tests for routine or confirmatory diagnosis of Lassa fever

Study Setting: Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria Irrua Specialist Teaching Hospital (ISTH) is 371-bed hospital serving people in Central, Northern and Southern Senatorial Districts of Edo State, as well as neighboring states The hospital lacked the laboratory diagnostic tools for Lassa Fever until 2008 and all cases were identified and managed based on clinical suspicion and post- management confirmation by sending blood samples of patients to larger medical centers within and outside the country The hospital currently is the only designated Institute of Lassa Fever Research and Control Center in West Africa and receives referrals of suspected cases of Lassa Fever across the country

Objective Our main objective was to examine how cases of Lassa Fever were diagnosed and managed in Irrua Specialist Teaching Hospital (ISTH) prior to the use of RT-PCR for confirmatory diagnosis of the disease. Our findings will inform the management of Lassa Fever in resource limited health facilities lacking RT-PCR diagnostic test in Lassa Fever endemic areas across West Africa

Methods This is a retrospective cross-sectional study using the case notes of suspected Lassa fever patients at ISTH between 2001- 2006 We reviewed the case notes of all patients with clinical suspicion of Lassa fever: a total of 96 cases

Results Most cases of Lassa Fever presented with: Fever, vomiting, headache, cough, sore throat, diarrhea Majority of cases (70%) presented a week after onset of symptoms In 30% of cases, the index of suspicion of Lassa fever was high and patients received treatment with ribavirin on the same day of presentation Majority did not commence therapy until 14 days after onset of symptoms About 76% of suspected cases received ribavirin therapy About 24% of suspected cases did not receive therapy with ribavirin throughout their stay in the hospital probably from stock out of medication

Results…cont The effect of ribavirin was most noticeable on day 3 after commencement of ribavirin therapy About 48% of Lassa fever cases presenting at ISTH between 2001 and 2006 died, 45% recovered and 6 % of them were either referred or discharged against medical advice About 22% of patients who did not receive ribavirin recovered as opposed to 58% of patients who received ribavirin

Conclusions Majority of patients did not present in the hospital or commence treatment with ribavirin more than 14 days after onset of symptom probably from mis-diagnosis and medication stock out Symptoms are similar to other common tropical febrile illness like malaria However, in Lassa Fever endemic areas, the index of suspicion should be high in patients presenting with symptoms listed above We recommend that in resource limited areas, there should be increased campaign to increase awareness of the disease

Limitations This study was limited by several factors: We found it challenging to locate some of the files of some Lassa fever cases from misfiling Additionally, some of the case files had inadequate documentation, were illegible and had missing pages Lastly, there was no known laboratory confirmation of the Lassa fever cases beyond crude clotting time. It is possible that some cases described as Lassa fever may have been another disease